THE SYNTHESIS AND PRECLINICAL STUDIES OF NEW TREATMENTS FOR NEURODEGENERATIVE DISEASE, DIABETES MELLITUS, CONGESTIVE HEART FAILURE, ONCOLOGIC AND IMMUNOLOGIC DISEASES

二甲双胍是目前应用最广泛的降糖药物之一，有效地用于治疗2型糖尿病。除了抗糖尿病作用外，二甲双胍似乎还具有重要的其他特性，这些特性在药理学上可能与人类的长期健康和福利有关。因此，在NIA的IRP中，正在对啮齿动物进行转化研究，以评估二甲双胍对啮齿动物健康相关的药效学测量的潜在有益作用，这些药效学测量与正常饮食和各种饮食（包括高脂肪饮食）有关。药代动力学——具体来说，二甲双胍血液和组织水平需要解释药效学数据，并有助于跨物种的翻译研究——重点是人类。本任务令支持在IRP NIA研究中生成的血浆和组织样本中二甲双胍药物水平的定量分析。

Metformin is one of the most widely used glucose-lowering drugs that is effectively used for the current treatment of type 2 diabetes mellitus. In addition to anti-diabetic action, metformin appears to possess important additional properties that may be pharmacologically relevant to long-term human health and welfare. Translational studies are therefore being undertaken in rodents within IRP, NIA, to evaluate potentially beneficial actions of metformin on a number of pharmacodynamics measures of relevance to health in rodents administered normal and assorted diets – including high fat. Pharmacokinetics – specifically, metformin blood and tissue levels are required to interpret pharmacodynamic data and aid in translation studies across species – with an emphasis on humans. This Task Order supports the quantitative analysis of metformin drug levels in plasma and tissue samples generated in IRP NIA research studies.